Century Therapeutics (IPSC) Non-Current Deferred Tax Liability (2022 - 2026)

Century Therapeutics (IPSC) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $4.3 million in Q1 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 1.67% year-over-year to $4.3 million in Q1 2026; TTM through Mar 2026 was $4.3 million, a 1.67% decrease from a year earlier, with the FY2025 full-year figure at $4.3 million, down 1.67% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $4.3 million, roughly flat from $4.3 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for IPSC reached as high as $4.4 million in Q4 2024 and fell as low as $5000.0 in Q4 2022.
• Historically, Non-Current Deferred Tax Liability has averaged $3.7 million across 4 years, with a median of $4.3 million in 2025.
• On a YoY basis, Non-Current Deferred Tax Liability climbed as much as 29.95% in 2025 and fell as far as 1.67% in 2025.
• Year by year, Non-Current Deferred Tax Liability stood at $5000.0 in 2022, then jumped by 87380.0% to $4.4 million in 2024, then dropped by 1.67% to $4.3 million in 2025, then changed by 0.0% to $4.3 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $4.3 million in Q1 2026, $4.3 million in Q4 2025, and $4.4 million in Q3 2025.